Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2) - Dataset (ID:20272)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule 1 | Small Molecule 2 | Small Mol 1 Concentration | Small Mol 2 Concentration | Small Mol Conc Unit | Time Point | Time Point Unit | Replicate | Total Number of Cells (Nuclei) | Number of Apoptotic Cells | Relative Viability | Mean Relative Viability | Apoptosis Fraction | Mean Apoptosis Fraction |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 3.160 | uM | 72 | hr | 2 | 757 | 37 | 0.7070 | 0.6959 | 0.0489 | 0.0496 |
COLO 858 | Vemurafenib | PF562271 | 0.100 | 3.160 | uM | 72 | hr | 2 | 723 | 550 | 0.0312 | 0.0290 | 0.7607 | 0.7843 |
COLO 858 | Vemurafenib | Defactinib | 0.100 | 0.000 | uM | 72 | hr | 3 | 4258 | 369 | 0.4617 | 0.4516 | 0.0867 | 0.0851 |
COLO 858 | Vemurafenib | Defactinib | 0.100 | 0.000 | uM | 72 | hr | 2 | 4062 | 356 | 0.4400 | 0.4516 | 0.0876 | 0.0851 |
COLO 858 | Vemurafenib | Defactinib | 0.100 | 0.000 | uM | 72 | hr | 1 | 4152 | 336 | 0.4531 | 0.4516 | 0.0809 | 0.0851 |
WM-115 | Vemurafenib | JNK-IN-8 | 0.100 | 1.000 | uM | 72 | hr | 1 | 3214 | 278 | 0.7426 | 0.7117 | 0.0865 | 0.0820 |
A-375 | Vemurafenib | Dasatinib | 0.100 | 3.160 | uM | 72 | hr | 2 | 1659 | 68 | 0.0806 | 0.0917 | 0.0410 | 0.0407 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 1.000 | uM | 72 | hr | 3 | 563 | 36 | 0.5175 | 0.7182 | 0.0639 | 0.0494 |
A-375 | Vemurafenib | Saracatinib | 0.100 | 0.000 | uM | 72 | hr | 3 | 7818 | 140 | 0.4019 | 0.4364 | 0.0179 | 0.0207 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 3.160 | uM | 72 | hr | 3 | 548 | 26 | 0.5126 | 0.6959 | 0.0474 | 0.0496 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 0.316 | uM | 72 | hr | 3 | 997 | 51 | 0.9290 | 0.8164 | 0.0512 | 0.0519 |
A-375 | Vemurafenib | Dasatinib | 0.100 | 3.160 | uM | 72 | hr | 1 | 2327 | 89 | 0.1133 | 0.0917 | 0.0382 | 0.0407 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 0.316 | uM | 72 | hr | 1 | 734 | 32 | 0.6894 | 0.8164 | 0.0436 | 0.0519 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 0.316 | uM | 72 | hr | 2 | 901 | 55 | 0.8308 | 0.8164 | 0.0610 | 0.0519 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 1.000 | uM | 72 | hr | 1 | 985 | 40 | 0.9280 | 0.7182 | 0.0406 | 0.0494 |
COLO 858 | Vemurafenib | Saracatinib | 0.100 | 3.160 | uM | 72 | hr | 3 | 1227 | 369 | 0.1453 | 0.1780 | 0.3007 | 0.3147 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 0.000 | uM | 72 | hr | 1 | 721 | 33 | 0.6756 | 0.8036 | 0.0458 | 0.0497 |
COLO 858 | Vemurafenib | Saracatinib | 0.100 | 3.160 | uM | 72 | hr | 1 | 1836 | 631 | 0.2041 | 0.1780 | 0.3437 | 0.3147 |
COLO 858 | Vemurafenib | Saracatinib | 0.100 | 3.160 | uM | 72 | hr | 2 | 1555 | 466 | 0.1845 | 0.1780 | 0.2997 | 0.3147 |
MMAC-SF | Vemurafenib | JNK-IN-8 | 0.100 | 0.000 | uM | 72 | hr | 2 | 913 | 53 | 0.8445 | 0.8036 | 0.0581 | 0.0497 |
COLO 858 | Vemurafenib | Saracatinib | 0.100 | 1.000 | uM | 72 | hr | 1 | 1775 | 484 | 0.2187 | 0.3290 | 0.2727 | 0.2076 |
COLO 858 | Vemurafenib | Saracatinib | 0.100 | 1.000 | uM | 72 | hr | 2 | 1561 | 404 | 0.1960 | 0.3290 | 0.2588 | 0.2076 |
WM-115 | Vemurafenib | JNK-IN-8 | 0.100 | 0.316 | uM | 72 | hr | 2 | 3200 | 257 | 0.7444 | 0.7245 | 0.0803 | 0.0810 |
COLO 858 | Vemurafenib | Saracatinib | 0.100 | 0.316 | uM | 72 | hr | 3 | 2269 | 427 | 0.3120 | 0.2723 | 0.1882 | 0.1881 |
COLO 858 | Vemurafenib | Saracatinib | 0.100 | 1.000 | uM | 72 | hr | 3 | 3719 | 340 | 0.5724 | 0.3290 | 0.0914 | 0.2076 |